Wedbush Reiterates a Buy Rating on Xoma Corp (XOMA)

By Jason Carr

Wedbush analyst Liana Moussatos reiterated a Buy rating on Xoma Corp (XOMAResearch Report) yesterday and set a price target of $26. The company’s shares opened today at $14.91.

According to TipRanks.com, Moussatos has currently no stars on a ranking scale of 0-5 stars, with an average return of -9.5% and a 34.4% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics Inc, Allena Pharmaceuticals Inc, and Catabasis Pharmaceuticals.

Currently, the analyst consensus on Xoma Corp is a Moderate Buy with an average price target of $31.

See today’s analyst top recommended stocks >>

The company has a one-year high of $25.99 and a one-year low of $11.02. Currently, Xoma Corp has an average volume of 61.24K.

Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of XOMA in relation to earlier this year. Most recently, in December 2018, James Neal, the CEO of XOMA bought 678 shares for a total of $8,814.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

XOMA Corp. engages in the discovery and development of innovative therapeutics derived from unique platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Berkeley, CA.